Pre-Clinical Tests of an Integrated CMOS Biomolecular Sensor for Cardiac Diseases Diagnosis.
Jen-Kuang LeeI-Shun WangChi-Hsien HuangYih-Fan ChenNien-Tsu HuangChih-Ting LinPublished in: Sensors (Basel, Switzerland) (2017)
Coronary artery disease and its related complications pose great threats to human health. In this work, we aim to clinically evaluate a CMOS field-effect biomolecular sensor for cardiac biomarkers, cardiac-specific troponin-I (cTnI), N-terminal prohormone brain natriuretic peptide (NT-proBNP), and interleukin-6 (IL-6). The CMOS biosensor is implemented via a standard commercialized 0.35 μm CMOS process. To validate the sensing characteristics, in buffer conditions, the developed CMOS biosensor has identified the detection limits of IL-6, cTnI, and NT-proBNP as being 45 pM, 32 pM, and 32 pM, respectively. In clinical serum conditions, furthermore, the developed CMOS biosensor performs a good correlation with an enzyme-linked immuno-sorbent assay (ELISA) obtained from a hospital central laboratory. Based on this work, the CMOS field-effect biosensor poses good potential for accomplishing the needs of a point-of-care testing (POCT) system for heart disease diagnosis.
Keyphrases
- human health
- label free
- particulate matter
- gold nanoparticles
- sensitive detection
- coronary artery disease
- air pollution
- risk assessment
- left ventricular
- quantum dots
- heavy metals
- polycyclic aromatic hydrocarbons
- climate change
- pulmonary hypertension
- type diabetes
- risk factors
- percutaneous coronary intervention
- cardiovascular events
- water soluble
- high resolution
- multiple sclerosis
- blood brain barrier
- single cell
- cerebral ischemia
- electronic health record